Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

CRIS

Curis (CRIS)

Curis Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CRIS
DateHeureSourceTitreSymboleSociété
14/06/202422h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRISCuris Inc
23/05/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRISCuris Inc
23/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRISCuris Inc
14/05/202422h00PR Newswire (US)Curis Announces Additional Data from TakeAim Leukemia StudyNASDAQ:CRISCuris Inc
10/05/202414h00PR Newswire (US)Curis to Present Updated Data from the TakeAim Leukemia StudyNASDAQ:CRISCuris Inc
07/05/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRISCuris Inc
07/05/202414h00PR Newswire (US)Curis Provides First Quarter 2024 Business UpdateNASDAQ:CRISCuris Inc
30/04/202414h00PR Newswire (US)Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024NASDAQ:CRISCuris Inc
05/04/202413h30PR Newswire (US)Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:CRISCuris Inc
04/04/202413h30PR Newswire (US)Curis to Present at Upcoming Healthcare Conferences in AprilNASDAQ:CRISCuris Inc
12/02/202422h16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CRISCuris Inc
08/02/202422h27Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CRISCuris Inc
08/02/202422h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRISCuris Inc
08/02/202414h00PR Newswire (US)Curis Provides Fourth Quarter 2023 Business UpdateNASDAQ:CRISCuris Inc
01/02/202414h00PR Newswire (US)Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024NASDAQ:CRISCuris Inc
21/12/202322h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:CRISCuris Inc
12/12/202314h00PR Newswire (US)Curis Announces Initial Combination Study Data from its TakeAim Lymphoma StudyNASDAQ:CRISCuris Inc
11/12/202314h00PR Newswire (US)Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH ConferenceNASDAQ:CRISCuris Inc
06/12/202314h00PR Newswire (US)Curis Announces Three Presentations at ASHNASDAQ:CRISCuris Inc
05/12/202314h00PR Newswire (US)Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in MelanomaNASDAQ:CRISCuris Inc
02/11/202313h00PR Newswire (US)Curis Provides Third Quarter 2023 Business UpdateNASDAQ:CRISCuris Inc
26/10/202314h30PR Newswire (US)Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023NASDAQ:CRISCuris Inc
28/09/202322h05Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CRISCuris Inc
12/09/202314h00PR Newswire (US)Curis Announces Date for the 2nd Symposium on IRAK4 in CancerNASDAQ:CRISCuris Inc
06/09/202314h13PR Newswire (US)Curis to Present at Upcoming Healthcare Conferences in SeptemberNASDAQ:CRISCuris Inc
18/08/202322h02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CRISCuris Inc
04/08/202322h09Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CRISCuris Inc
03/08/202322h01PR Newswire (US)Curis Provides Second Quarter 2023 Business UpdateNASDAQ:CRISCuris Inc
28/07/202300h25PR Newswire (US)Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023NASDAQ:CRISCuris Inc
06/07/202322h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CRISCuris Inc
 Showing the most relevant articles for your search:NASDAQ:CRIS